SIGNIFICANT CONCENTRATIONS |
12 Months Ended |
|---|---|
Dec. 31, 2015 | |
| SIGNIFICANT CONCENTRATIONS | |
| SIGNIFICANT CONCENTRATIONS |
3. SIGNIFICANT CONCENTRATIONS For the year ended December 31, 2015, BMS, Aclaris and another third party accounted for 60%, 28% and 12% of our revenues, respectively. For the year ended December 31, 2014, AZ accounted for all of our revenues. For the year ended December 31, 2013, AZ and Daiichi accounted for 80% and 20% of our revenues, respectively. As of December 31, 2015, we had accounts receivable from BMS of $203,000 relating to the performance of research activities. As of December 31, 2014, we had receivable from AZ of $5.8 million in consideration for AZ’s decision to continue its development of R256 in asthma.
|
| X | ||||||||||
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|